Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis.

Evan MadillBrian C HealyNegar MolazadehMariann Polgar-TurcsanyiBonnie I GlanzHoward L WeinerTanuja Chitinis

Published in: Annals of clinical and translational neurology (2024)

sGFAP helps to predict PIRA, future gait aid, and conversion to SPMS in a large cohort of MS patients. Our data suggest that baseline levels may be more useful than the change over time.

Keyphrases

multiple sclerosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
mass spectrometry
peritoneal dialysis
electronic health record
machine learning
big data
patient reported
amino acid
cerebral palsy